Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jbspin.2023.105522 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-induced liver injury related to avacopan therapy.
Rheumatology (Oxford)
December 2024
Department of Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan.
Objectives: The efficacy of avacopan as remission induction therapy for Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (AAV) is well-established. However, concerns regarding liver injury post-avacopan treatment remain, especially in Japan. Therefore, this study aimed to investigate drug-induced liver injury (DILI) associated with avacopan treatment.
View Article and Find Full Text PDFAvacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview.
Expert Rev Clin Pharmacol
November 2024
Department of Nephrology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Introduction: ANCA-associated vasculitis (AAV) is a rare, life-threatening disease which may result in serious pulmonary and kidney damage. Cyclophosphamide or rituximab and high-dose glucocorticoids significantly improved patient outcomes, but at the expense of severe complications. Moreover, many patients still relapse and bear a significant burden of both disease- and treatment-related complications.
View Article and Find Full Text PDFAvacopan in the treatment of refractory scleritis secondary to granulomatosis with polyangiitis: A case report.
Eur J Ophthalmol
October 2024
Uveitis and Scleritis Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
Purpose: Avacopan is a novel C5a receptor inhibitor which was recently licensed for treatment of severe granulomatosis with polyangiitis (GPA) in the European Union and the United Kingdom. To the best of our knowledge, this is the first described case on initial ophthalmic outcomes in a patient with severe GPA and concurrent refractory scleritis treated with avacopan.
Case Description: We present a case of de novo scleritis in a 77-year-old male with a background of retinitis pigmentosa with Argus II implant in situ.
Case report: Avacopan-induced severe liver injury with prolonged jaundice and lipoprotein X-induced dyslipidemia.
Int J Rheum Dis
November 2024
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!